We were thrilled to see John Oliver educate the nation about the pharmaceutical industry’s lesser known marketing tactics. We were even more delighted that he showcased two NPA members on the side of reform! This hilarious (occasionally edgy) take-down is so powerful that it garnered national media attention in its own right. We offer it to you here, with a special opportunity to hear more from two of the cause’s leading lights:
NPA invites you to join two incredible leaders—Drs. Shahram Ahari and Jerry Avorn—for a frank, insiders’ conversation about how drug marketers manipulate physicians and what can be done to ensure that our medical educators aren’t pitching product.
What: Evening Webinar: Marketing to Doctors—An Insiders’ (Unsettling) Guide
When: Thursday, March 26, 8 pm ET
CLICK HERE TO REGISTER
The presentation will be moderated by NPA’s President, Dr. Bill Jordan. Register now and protect the hour!
Shahram Ahari MD, MPH is a former pharmaceutical sales representative turned health advocate. After leaving Eli Lilly’s elite neuroscience division selling two block-buster medications, Shahram dedicated his career to issues related to public health and social justice. Drawing from his research and experience, he has lectured extensively on the impact of drug marketing on physician prescribing, public health, medical ethics, policy, and research. His advocacy work has yielded media interviews, policy changes, and testimony to multiple state governments, Congress, and the Supreme Court.
Shahram received his bachelors in Asian studies, biochemistry, and molecular biology from Rutgers College, completed his master’s in public health from the University of California, Berkeley, and his medical degree from the University of California, Davis. He is currently an emergency medicine resident at the University of Rochester.
Jerry Avorn, MD is Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. An internist and drug epidemiologist, he studies the intended and adverse effects of prescription drugs, physician prescribing practices, and medication policy. The division he founded and leads comprises physicians, epidemiologists, health policy analysts, statisticians, and computer scientists who work together to analyze patterns of utilization and outcomes of prescription drugs in numerous settings. Dr. Avorn pioneered the “academic detailing” approach to continuing medical education, in which non-commercial, evidence-based information about drugs is provided to doctors through educational outreach programs run by public-sector sponsors. Such programs are now in use in the U.S., Canada, Australia, and Europe. (see www.AlosaFoundation.org.) Dr. Avorn did his undergraduate work at Columbia University in 1969, received the M.D. from Harvard Medical School in 1974, and completed a residency in internal medicine at the Beth Israel Hospital in Boston. He has served as a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and is the author or co-author of over 400 papers in the medical literature on medication use and its outcomes, and of the book, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, now in its 11th printing.
Division website: www.DrugEpi.org
Book website: www.PowerfulMedicines.org